Findings

What do systematic reviews say?

16 questions · 16 findings · 2 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 37.5%GRADE not reported 0 · 0%Very low 8 · 50%Low 2 · 12.5%Moderate 0 · 0%High 0 · 0%

Glitazone vs placebo

HbA1c (%) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 88 participants
Very low

Glitazone vs placebo

FBG (mmol/L) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 233 participants
Very low

Glitazone vs placebo

Death (all causes) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 52 participants
Very low

Glitazone vs placebo

All cardiovascular death · people with diabetes and CKD

The review found no eligible studies for this question.

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glitazone vs placebo

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 222 participants
Very low

Glitazone vs placebo

eGFR · people with diabetes and CKD

The review found no eligible studies for this question.

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glitazone vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 70 participants
Very low

Glitazone vs placebo

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Very low

Glitazones and insulin vs placebo and insulin

Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glitazones and insulin vs placebo and insulin

Delayed graft function · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glitazones and insulin vs placebo and insulin

HbA1c (%) · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Very low

Glitazones and insulin vs placebo and insulin

FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 120 participants
Low

Glitazones and insulin vs placebo and insulin

Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Very low

Glitazones and insulin vs placebo and insulin

Death (any cause) · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glitazones and insulin vs placebo and insulin

Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glitazones and insulin vs placebo and insulin

Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 71 participants
Low